1. Home
  2. MUJ vs AKBA Comparison

MUJ vs AKBA Comparison

Compare MUJ & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniHoldings New Jersey Quality Fund Inc.

MUJ

Blackrock MuniHoldings New Jersey Quality Fund Inc.

HOLD

Current Price

$12.47

Market Cap

662.2M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUJ
AKBA
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
662.2M
729.1M
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
MUJ
AKBA
Price
$12.47
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$5.92
AVG Volume (30 Days)
98.7K
3.3M
Earning Date
01-01-0001
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
N/A
N/A
Revenue This Year
N/A
$47.43
Revenue Next Year
N/A
$17.65
P/E Ratio
N/A
$40.17
Revenue Growth
N/A
N/A
52 Week Low
$10.50
$1.14
52 Week High
$12.50
$4.08

Technical Indicators

Market Signals
Indicator
MUJ
AKBA
Relative Strength Index (RSI) 66.55 36.12
Support Level $11.93 N/A
Resistance Level $12.48 $1.57
Average True Range (ATR) 0.11 0.10
MACD 0.01 -0.02
Stochastic Oscillator 91.11 14.13

Price Performance

Historical Comparison
MUJ
AKBA

About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.

BlackRock MuniHoldings New Jersey Quality Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund mainly invests in long-term, investment-grade municipal obligations exempt from U.S federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and New Jersey personal income taxes, with remaining maturities of one year or more at the time of investment. The rest of its managed assets can be invested in securities that are rated below investment grade (or similar instruments), or invested directly in securities or synthetically through the use of derivatives.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: